



**Denise I. Campagnolo, M.D.**

Faculty, Barrow Neuroimmunology Program  
Director, Clinical Research, Neuroimmunology Program  
St. Joseph's Hospital and Medical Center  
Barrow Neurology Clinics  
500 West Thomas Road, Suite 710  
Phoenix, Arizona 85013  
602-406-3887 Telephone  
602-798-0697 Facsimile  
[denise.campagnolo@chw.edu](mailto:denise.campagnolo@chw.edu) E-mail

**EDUCATION**

- 1980 – 1981     Randolph-Macon College  
                    Ashland, Virginia  
                    Degree: None
- 1981 – 1981     Ohio Dominican College  
                    Columbus, Ohio  
                    Degree: None
- 1982 – 1984     Ohio State University  
                    Columbus, Ohio  
                    Degree: B.S.
- 1992 – 1993     University of Medicine and Dentistry of New Jersey  
                    Newark, New Jersey  
                    Degree: M.S., Neuroscience

**MEDICAL SCHOOL**

- 1984 – 1988     Ohio State University College of Medicine  
                    Columbus, Ohio  
                    Degree: M. D.

**INTERNSHIP**

- 1988             General Surgery Training  
                    St. Barnabas Medical Center  
                    Livingston, New Jersey
- 1988 – 1989     Rotating Transitional Internship  
                    Riverside Methodist Hospital  
                    Columbus, Ohio

**RESIDENCY**

- 1989 – 1991      Resident  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
Newark, New Jersey
- 1991 – 1992      Chief Resident  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
Newark, New Jersey

**FELLOWSHIP**

- 1992 – 1993      Research Fellowship  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
Newark, New Jersey

**CURRENT LICENSURE**

State of Arizona  
License Number: 32640

**BOARD CERTIFICATIONS**

- 1998, 2007      American Board of Physical Medicine and Rehabilitation  
Subspecialty: Spinal Cord Injury Medicine
- 1994, 2004      American Board of Electrodiagnostic Medicine, Diplomate
- 1993, 2003      American Board of Physical Medicine and Rehabilitation

**CURRENT POSITIONS**

- 2004 – Present    Investigator  
Barrow Neurology Clinics  
St. Joseph's Hospital and Medical Center  
Phoenix, Arizona
- 2004 – Present    Director of Multiple Sclerosis Clinical Research  
Staff Psychiatrist  
Barrow Neurology Clinics  
St. Joseph's Hospital and Medical Center  
Phoenix, Arizona

- 2005 – 2008      Director, NARCOMS Project for Consortium of MS Centers  
Phoenix, Arizona
- 2004 – Present    Clinical Faculty/Adjunct  
Center for Adaptive Neural Systems  
Arizona State University  
Tempe, Arizona

**PREVIOUS POSITIONS AND APPOINTMENTS**

- 2000 – 2004      Associate Professor, Physical Medicine and Rehabilitation  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
University Hospital, B-261  
Newark, New Jersey
- 1998 – 2004      Consulting Privileges  
Overlook Hospital  
Summit, New Jersey
- 1993 – 2004      Staff Physiatrist, Clinical Director of SCI Program  
Department of Physical Medicine and Rehabilitation  
University Hospital  
Newark, New Jersey
- 1996 – 2001      Consulting Privileges  
Bayonne Hospital  
Bayonne, New Jersey
- 1995 – 2000      Assistant Professor, Physical Medicine and Rehabilitation  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
University Hospital, B-261  
Newark, New Jersey
- 1993 – 1995      Instructor  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
University Hospital, B-261  
Newark, New Jersey
- 1991 – 1992      Clinical Instructor II  
Department of Physical Medicine and Rehabilitation  
UMDNJ-New Jersey Medical School  
University Hospital, B-261  
Newark, New Jersey

**HONORS**

- 2000 Outstanding Women in Somerset County  
Medicine/Health Services
- 1999 Alumni Award  
UMDNJ-Department of Physical Medicine and Rehabilitation
- 1999 Humanism in Medicine Award  
Healthcare Foundation of New Jersey
- 1995 Annual Teaching Award  
UMDNJ-NJMS Department of Physical Medicine and Rehabilitation
- 1994 Excellence in Research Writing Award  
American Journal of Physical Medicine and Rehabilitation
- 1993 Education and Research Foundation – Young Investigator’s Award  
American Academy of Physical Medicine and Rehabilitation
- 1988 Alpha Omega Alpha Honor Medical Society
- 1987 Third Place for Platform Presentation  
Landacre Society Research Forum  
Ohio State University College of Medicine

**CURRENT PROFESSIONAL MEMBERSHIPS**

- Alpha Omega Alpha Honor Medical Society
- Arizona Medical Association
- American Association of Neuromuscular & Electromyography Diagnostic Medicine  
(AANEM)
- Association of Academic Physiatrists
- American Paraplegia Society

**COMMITTEE MEMBERSHIPS**

- 2008 – Present University of Arizona College of Medicine, Phoenix, Medical Student Clerkship Directors Committee
- 2006 - Present SJHMC Institutional Review Board
- 2004 – Present BNI Neurology Graduate Medical Education Committee
- 2002 – Present American Paraplegia Society Research Committee
- 2001 – Present American Board of Physical Medicine and Rehabilitation Spinal Cord Injury Medicine Board Question Item Writing Committee
- 2003 – 2004 OSCE Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 2002 – 2004 PRIME 2005 Education Committee; UMDNJ-New Jersey Medical School
- 2000 – 2004 Chair, Graduate Medical Education Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 2000 – 2004 AAEM – Research Pilot Study Review Task Force
- 1999 – 2004 Women’s Talk Force Committee of the Association of Academic Physiatrists
- 1997 – 2004 Undergraduate Medical Education Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1996 – 2004 Clinical Practice Committee; University Hospital
- 1996 – 2004 Spinal Cord Medicine Fellowship Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1995 – 2004 Medical Fellowship Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1993 – 2004 Neurosurgical Advisory Group; University Hospital
- 1993 – 2004 Chair of the Spinal Cord Injury Program Committee; University Hospital
- 1992 – 2004 Match Committee; NJMS, Department of Physical Medicine and Rehabilitation
- 2000 – 2003 Graduate Medical Education Committee; UMDNJ-New Jersey Medical School
- 2001 – 2002 House staff Disciplinary and Impairment Ad Hoc Committee; UMDNJ – New

Jersey Medical School

- 1999 – 2001 Institutional Review Board; UMDNJ-New Jersey Medical School
- 1998 – 1999 Research Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1994 – 1999 Undergraduate Education Committee of the Association of Academic Physiatrists
- 1994 – 1998 Academic Programs and Policies Committee; UMDNJ-New Jersey Medical School
- 1993 – 1997 Clinical Curriculum Subcommittee; UMDNJ-New Jersey Medical School
- 1992 – 1997 Chair, Undergraduate Medical Education Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1991 – 1994 Graduate Medical Education Committee; University Hospital, Department of Physical Medicine and Rehabilitation
- 1991 – 1992 Medical Society of New Jersey Council of Public Health, Resident Representative
- 1991 – 1992 American Academy of Physical Medicine and Rehabilitation, Resident Physician Council, Research Committee, Northeast Representative

**EDITORIAL BOARDS**

- 2007 – Present Associate Editor, American Journal of Physical Medicine and Rehabilitation
- 2001 – Present Chief Editor, eMedicine – online textbook
- 1999 – Present Reviewer, Journal of spinal Cord Injury Medicine
- 1995 – Present Reviewer, Archives of Physical Medicine and Rehabilitation
- 1994 – Present Reviewer, American Journal of Physical Medicine and Rehabilitation

**GRANTS**

1. Spinal Cord Injury Education Grant, June 1995  
The Upjohn Company Grant Program # 00433  
Principal Investigator
2. Immune Function in Spinal Cord Injury. Henry H. Kessler Foundation Grant, September 1995  
Principal Investigator

3. Academic Information Technology Advisory Committee. Instructional Technology Grant 1996  
Principal Investigator
4. Immune System Dysfunction Following Spinal Cord Injury. Dean's Biomedical Research Grant, 1997  
Principal Investigator
5. Factors That Contribute to Infections During SCI Rehabilitation. PVA – Spinal Cord Research Foundation, 2001 – 2004  
Principal Investigator
6. Sympathetic Nervous System (SNS) Dysregulation and Diminished Cellular Immunity in Spinal Cord Injury. Christopher Reeve Paralysis Foundation, 2001 – 2003  
Co-Principal Investigator
7. Immunity and Health Following Spinal Cord Injury. NIH – K24 – Career Award, Start date July 1, 2004 – June 30 2009 Principal Investigator Awarded \$564,164.00
8. NK Cells as Surrogate Disease Marker in MS. Barrow Neurological Foundation 2007-2008 awarded \$ 69,696.00  
Principal Investigator

**CURRENT RESEARCH:**

1. Immunity and Spinal Cord Injury Study  
Principal Investigator
2. A Multinational, Multicenter, Randomized, Parallel-Group, Double-Blind Study, to Compare the Efficacy, Tolerability and Safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml Administered Once Daily by Subcutaneous Injection in Subjects with Relapsing Remitting (R-R) Multiple Sclerosis (MS)  
Principal Investigator
3. NARCOMS Patient Registry  
Co-Investigator
4. H-reflex to monitor motor pathway function in patients undergoing spine surgery  
Co-Investigator
5. A Longitudinal, Case-Control Study to Collect Medical and Epidemiological Data and Blood Samples for Research Into the Causes of Multiple Sclerosis and Selected Demyelinating Diseases

Co-Investigator

6. Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral xxxxx-SR in Subjects with Multiple Sclerosis  
Co-Investigator
7. Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral xxxxx-SR in Subjects with Multiple Sclerosis Who Participated in the xxxxx Trial  
Co-Investigator
8. Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral xxxxx-SR (10 mg b.i.d.) in Patients with Multiple Sclerosis  
Co-Investigator
9. Open-Label Extension Study to Evaluate the Safety, Tolerability and Activity of Oral xxxxx-SR in Patients with Multiple Sclerosis (MS) who Participated in the xxxxx Trial  
Co-Investigator
10. Development of Peripheral Blood and Urine Diagnostics and Biomarkers for Alzheimer's Disease ("Alzheimer's Diagnostic Study")  
Co-Investigator
11. An Immunological Study of Atorvastatin (Lipitor®) as Combination Therapy with Glatiramer Acetate (Copaxone®) versus Glatiramer Acetate Alone in Patients with Active Relapsing-Remitting Multiple Sclerosis (RRMS)  
Co-Investigator
12. Specimen and Data Collection and Archiving for Immunological Investigations Aiming to Understand the Immunological Mechanism of Multiple Sclerosis (MS) and Identify New Targets For Immune Therapies for Multiple Sclerosis and Other Autoimmune Diseases and Neuroinflammatory Disorders  
Co-Investigator
13. Gene Expression Assay of Patients with Multiple Sclerosis and Other Neurological Diseases, On and Off Immunological Therapy, Compared to Healthy Controls  
Co-Investigator
14. International, randomized, multicenter, phase IIIb study in patients with relapsing-remitting multiple sclerosis comparing over a treatment period of 104 weeks: Double-blinded safety, tolerability, and efficacy of Betaseron®/Betaferon® xxxxx micrograms (xxxxx MIU) and Betaseron®/Betaferon® xxxxx micrograms (xxxxx MIU), both given subcutaneously every other day; and Rater-blinded safety, tolerability, and efficacy of Betaseron®/Betaferon® subcutaneously every other day with Copaxone® 20 mg subcutaneously once daily  
Co-Investigator



15. International, multicenter, Phase IIIb study of subcutaneous every-other-day treatment of patients with relapsing multiple sclerosis with: (Phase A) double-blind Betaseron/Betaferon xxxxx µg or xxxxx µg or open-label Betaseron/Betaferon xxxxx µg and (Phase B) open-label Betaseron/Betaferon xxxxx µg  
Co-Investigator
16. Long-Term Follow-Up Health Survey of Subjects Previously Treated with xxxxx  
Co-Investigator
17. Impact of Neutralizing Antibodies on Interferon Responsive Genes Highlights Biomarker Response  
Co-Investigator
18. A Randomized, Multicenter, Placebo-Controlled and Active Reference (Glatiramer Acetate) Comparison Study to Evaluate the Efficacy and Safety of xxxxx in Subjects With Relapsing-Remitting Multiple Sclerosis  
Co-Investigator
19. A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of xxxxx in Subjects with Secondary Progressive Multiple Sclerosis  
Co-Investigator
20. A Phase II/III, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of xxxxx (MabThera®/Rituxan®) in Adults with Primary Progressive Multiple Sclerosis  
Co-Investigator
21. A Phase II, Proof-of-Concept, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of xxxxx (MabThera®/Rituxan®) in Adults with Relapsing-Remitting Multiple Sclerosis  
Co-Investigator
22. A Phase 3 Randomized, Rater-Blinded Study Comparing Two Annual Cycles of Intravenous Alemtuzumab to 3-Times Weekly Subcutaneous Interferon Beta-1a (Rebif®) in Treatment-Naïve Patients with Relapsing-Remitting Multiple Sclerosis  
Co-Investigator
23. A Phase 3, Randomized, Rater- and Dose-Blinded Study Comparing Two Annual Cycles of Intravenous Low- and High-Dose Alemtuzumab to Three-Times Weekly Subcutaneous Interferon Beta 1a (Rebif®) in Patients with Relapsing Remitting Multiple Sclerosis Who Have Relapsed On Therapy  
Co-Investigator

24. A Blood Test for Multiple Sclerosis: Detection and Analysis of a Circulating Multiple Sclerosis Associated Antigen  
Co-Investigator
25. A Randomized, Double-Blinded, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients with Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis  
Co-Investigator
26. A Multi-Center, Double-Blind, Randomized Study Comparing the Combined Use of Interferon Beta-1a and Glatiramer Acetate to Either Agent Alone in Patients with Relapsing Remitting Multiple Sclerosis  
Co-Investigator
27. Biomarkers in Multiple Sclerosis  
Co-Investigator
28. A 12-month double-blind, randomized, multicenter, active-controlled, parallel-group study comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered orally once daily versus interferon  $\beta$ -1a (Avonex®) administered i.m. once weekly in patients with relapsing-remitting multiple sclerosis with optional Extension Phase  
Co-Investigator
29. A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of xxxxx mg and xxxxx mg xxxxx (xxxxx) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis  
Co-Investigator
30. A Phase 2 Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab® in Patients with Active, Relapsing Forms of Multiple Sclerosis  
Co-Investigator
31. A Phase II, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Efficacy Study on Add-on Cladribine Tablet Therapy with Rebif® New Formulation in Multiple Sclerosis Subjects with Active Disease  
Co-Investigator
32. Online Validation of Multiple Sclerosis International Quality of Life (MuSI-QoL) Questionnaire  
Co-Investigator
33. A Multi-Centered, Two Arm, Open Label Extension Study (to protocol xxxxx) to Evaluate the Long-Term Safety and Efficacy of Short-Term Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) vs. Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis  
Co-Investigator

34. Immunological Studies for a Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis  
Co-Investigator
35. Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two doses of xxxxx over 24 weeks with a rater-blind MRI follow-up over 12 weeks  
Co-Investigator

**COMPLETED RESEARCH:**

1. The Impact of CarePartner Stress in Multiple Sclerosis  
Co-Principal Investigator
2. A 24-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose Finding, Safety, Tolerability, and Efficacy Study of the xxxxx in Subjects With Multiple Sclerosis With a 24-Week Double-Blind, Active Extension Phase  
Co-Investigator
3. Double-Blind, Placebo-Controlled, 21-Week, Parallel Group Study to Evaluate Safety and Efficacy of Oral xxxxx-SR (xxxxx mg B.I.D.) in Subjects with Multiple Sclerosis  
Co-Investigator
4. A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of xxxxx (xxxxx/xxxxx) in the Treatment of Pseudobulbar Affect in Patients with Multiple Sclerosis  
Co-Investigator
5. An Open-Label Multicenter Study to Assess the Safety of xxxxx (xxxxx/xxxxx) in the Treatment of Patients with Pseudobulbar Affect  
Co-Investigator
6. Randomized, Double-Blind, Placebo-Controlled Study to Compare the Effects of Different Dose Regimens of IGIV-Chromatography (IGIV-C), 10% Treatment on Relapses in Patients with Relapsing Remitting Multiple Sclerosis  
Co-Investigator
7. Phase I Trial of Immunotherapy with xxxxx Alone or Combined with Atorvastatin in Patients with Multiple Sclerosis  
Co-Investigator
8. An Exploratory Study of Blood Markers of Disease Activity in Multiple Sclerosis  
Co-Investigator

9. xxxxx Immunotherapy in Relapsing Remitting Multiple Sclerosis  
Co-Investigator
10. A Randomized, Rater-blinded, Multicenter, Parallel-group Study Comparing the Efficacy and Safety of Betaseron® xxxx ug Subcutaneously Every Other Day with Avonex® xxxxx ug Intramuscularly Once per Week in Relapsing-remitting Multiple Sclerosis Patients Previously Treated with Avonex®  
Co-Investigator
11. A Multi-Center, Randomized, Blinded, Parallel-Group Study of AVONEX® Compared with AVONEX® in Combination with Oral Methotrexate, Intravenous Methylprednisolone, or Both in Subjects with Relapsing-Remitting Multiple Sclerosis Who Have Breakthrough Disease on AVONEX® Monotherapy  
Co-Investigator
12. A Randomized, Double-blind, Placebo-controlled, Parallel group, Dose-ranging Study to Investigate the MRI Efficacy and the Safety of Three Months Administration of xxxxx (xxxxx-xxxxx mg twice daily) in Subjects with Relapsing Multiple Sclerosis  
Co-Investigator
13. Quality of Life/COST Study  
Co-Investigator
14. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of xxxxx in Patients with Relapsing Multiple Sclerosis  
Co-Investigator
15. Phase IV, multicenter, open label, randomized study of Rebif xxxxx mcg administered three times per week by subcutaneous injection compared with Copaxone® xxxxx mg administered daily by subcutaneous injection in the treatment of relapsing remitting multiple sclerosis  
Co-Investigator
16. MuSI-QoL Project: Field Study Design  
Co-Investigator
17. A Multi-Center, Randomized, Single-Blind, Parallel Group Study to Compare the Efficacy, Tolerability and Safety of Copaxone® to that of High Dose Interferon (Betaseron® or Rebif®) in the Treatment of Relapsing Multiple Sclerosis Patients  
Co-Investigator

18. A Multi-Centered, Randomized, Two-Arm, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Induction Treatment with Mitoxantrone (Novantrone®) Preceding Treatment with Glatiramer Acetate (Copaxone®) versus Chronic Treatment with Glatiramer Acetate Alone in Relapsing Forms of Multiple Sclerosis  
Co-Investigator
19. A Multi-Centered, Randomized, Double-Blind, Placebo Controlled Study Assessing the Add-On Effect of Oral Steroids in Relapsing Remitting Multiple Sclerosis Subjects Treated with Glatiramer Acetate (GA)  
Co-Investigator

### **BOOKS**

*Spinal Cord Medicine*. Eds: Kirshblum S, **Campagnolo DI**, DeLisa J. Lippincott Williams and Wilkins: publication date January 2002.

### **PUBLICATIONS**

1. **Campagnolo DI**, Gower WR, Fabri J, Sparks J, Mekhjian HS, O'Dorisio TM, Ellison EC. Effect of Somatostatin Analogue (SMS 201-995) on Molecular Species of Gastrin in Gastrinoma. *Surgery* 102:982-987, 1987 Dec.
2. Bach J, **Campagnolo DI**, Hoeman S. Life Satisfaction of Individuals with Duchenne Muscular Dystrophy Using Long-Term Mechanical Ventilatory Support. *American Journal of Physical Medicine and Rehabilitation* 70(3):129-135, 1991 Jun.
3. DeLisa JA, Jain SS, **Campagnolo DI**, McCutcheon P. Selecting a Physical Medicine and Rehabilitation Residency. *American Journal of Physical Medicine and Rehabilitation* 71(2):72-76, 1992 Apr.
4. Bach J, **Campagnolo DI**. Psychosocial Adjustment of Post Poliomyelitis Ventilator Assisted Individuals. *Archives of Physical Medicine and Rehabilitation* 73(10):934-939, 1992 Oct.
5. DeLisa JA, Jain SS, **Campagnolo DI**, McCutcheon P. A Method to Assess Trainee Profiles of Medical Students Attracted to Our Physical Medicine and Rehabilitation Residency Training Program. *American Journal of Physical Medicine and Rehabilitation* 72(1):2-5, 1993 Feb.
6. Jain SS, DeLisa JA, **Campagnolo DI**. Chief Residents in Physiatry: Expectations Versus Training. *American Journal of Physical Medicine and Rehabilitation* 72:262-265, 1993 Oct.
7. **Campagnolo DI**, Linsenmeyer TA, Jacalan C, Pak N, Averill A. Prevalence of urinary incontinence after brain injury. *Neuro Rehabilitation*. 1994;4(4):255-258.

8. Malanga G, **Campagnolo DI**. Clarification of the 'Pronator Reflex.' *American Journal of Physical Medicine and Rehabilitation*. 1994;73(5):338-340.
9. Kirshblum S, **Campagnolo DI**. Heterotopic Ossification after Total Hip Replacement. *Journal of Back and Musculoskeletal Medicine*. 1994;4(3):207-217.
10. Katz RT, **Campagnolo DI**. Pharmacologic Management of Spasticity. *PM&R State of the Art Review*. 1994;8(3):473-480.
11. DeLisa JA, Jain SS, **Campagnolo DI**. Factors Used by Physical Medicine and Rehabilitation Residency Training Directors to Select Their Residents. *American Journal of Physical Medicine and Rehabilitation* 73(3):152-156, 1994 Jun.
12. Jain SS, DeLisa JA, **Campagnolo DI**. Methods of Evaluation of Physical Medicine and Rehabilitation Residents' Clinical Competency. *American Journal of Physical Medicine and Rehabilitation* 73(4):234-239, 1994 Jul-Aug.
13. **Campagnolo DI**, Keller SE, DeLisa JA, Sipski ML, Glick T, Schleifer SJ. Alteration of Immune System Function in Tetraplegics: A Pilot Study. *American Journal of Physical Medicine and Rehabilitation* 73(6):387-393. 1994 Nov-Dec.
14. Katz RT, **Campagnolo DI**, Goldberg G, Parker JC, Pine ZM, Whyte J. Critical Evaluation of Clinical Research. *Archives of Physical Medicine and Rehabilitation* 76(1):82-93, 1995 Jan.
15. DeLisa JA, Jain SS, **Campagnolo DI**, Kirshblum SC, Findley T. Factors Influencing the Specialty Choice of the Physical Medicine and Rehabilitation Graduating Class of 1994 and the Entering Class of 1995. *American Journal of Physical Medicine and Rehabilitation* 74(4):262-270, 1995 Jul-Aug.
16. Linsenmeyer TA, **Campagnolo DI**, Chou I. Silent Autonomic Dysreflexia During Voiding in Men with Spinal Cord Injuries. *Journal of Urology* 155(2):519-522, 1996 Feb.
17. **Campagnolo DI**, Davis BA, Blacksin MF. Computed Tomography – Guided Aspiration of a Ganglion Cyst of the Anterior Cruciate Ligament: A Case Report. *Archives of Physical Medicine & Rehabilitation* 77(7):732-3, 1996 Jul.
18. **Campagnolo DI**, DeLisa JA. Drugs used to improve recovery following spinal cord injury. *Medula Espina*. 1996;July:137-142.
19. DeLisa JA, Kirshblum SC, Jain SS, **Campagnolo DI**, Johnston M, Wood KD, Findley T. Practice and Career Satisfaction Among Physiatrists. A National Survey. *American Journal of Physical Medicine and Rehabilitation* 76(2):90-101, 1997 Mar-Apr.
20. **Campagnolo DI**, Esquieres RE, Kopacz KJ. Effect of Timing of Stabilization on Length of Stay and Medical Complications Following Spinal Cord Injury. *Journal of Spinal Cord Medicine* 20(3):331-334, 1997 Jul.

21. **Campagnolo DI**, Bartlett JA, Keller SE, Sanchez W, Oza R. Impaired Phagocytosis of Staphylococcus Aureus in Complete Tetraplegics. *American Journal of PM&R* 6(4):276-280, 1997 Jul-Aug.
22. **Campagnolo DI**, Melchiorre PI. Bilateral patellar tendon rupture after minor trauma. *European Journal of Physical Medicine and Rehabilitation*. 1998;8(3):74-76.
23. **Campagnolo DI**, DeLisa JA. Medical complications of spinal cord injury. *J Clinical Rehabilitation*. 1998;7(4):402-414.
24. Kirshblum SC, DeLisa JA, **Campagnolo DI**. Mandatory Clerkship in Physical Medicine and Rehabilitation: Effect on Medical Students' Knowledge of Physiatry. *Archives of Physical Medicine & Rehabilitation* 79(1):10-3, 1998 Jan.
25. Nadler S, **Campagnolo DI**, Tomaiio A, Stitik T. High Lumbosacral Disc: A Diagnostic and Treatment Dilemma. *American Journal of PM&R* 77(6):538-544, 1998 Nov-Dec.
26. **Campagnolo DI**, Bartlett JA, Chatterton R, Keller SE. Adrenal and Pituitary Hormone Patterns Following Spinal Cord Injury. *American Journal of PM&R* 78(4):361-366, 1999 Jul-Aug.
27. **Campagnolo DI**, Bartlett JA, Keller SE. Influence of Neurologic Level of Injury on Immune Function Following SCI: A Review. *Journal of Spinal Cord Medicine* 23(2):121-128, 2000.
28. **Campagnolo DI**, Romello MA, Park YI, Foye PM, DeLisa JA. A Technique for Studying Conduction in the Lateral Cutaneous Nerve of the Calf. *Muscle and Nerve* 23(8):1277-1279, 2000 Aug.
29. Qian T, **Campagnolo DI**, Kirshblum S. High-Dose Methylprednisolone May Do More Harm for Spinal Cord Injury. *Medical Hypotheses* 55(5):452-453, 2000 Nov.
30. Kirshblum SC, Memmo P, Kim N, **Campagnolo DI**, Millis S. Comparison of the Revised 2000 ASIA Classification Standards with the 1996 Guidelines. *American Journal of PM&R* 81(7):502-505, 2002 Jul.
31. **Campagnolo DI**, Filart RA, Millis SR, Lann DE. The Appropriateness of the Ifield Psychiatric Symptom Index as a Screening Tool for Depressive Symptomatology in Persons with Spinal Cord Injury. *Journal of Spinal Cord Medicine* 25(2):129-132, 2002.
32. **Campagnolo DI**. Stier KT. Sanchez W. Foye PM. DeLisa JA. Spinal Cord Injury Computer-Assisted Instruction for Medical Students. *American Journal of Physical Medicine & Rehabilitation* 82(4):316-9, 2003 Apr.
33. Tomassoni P, **Campagnolo DI**. Autonomic Dysreflexia: One More Way EMS Can Positively Affect Patient Survival. *Journal of Emergency Medical Services* 28(12):46-51 2003 Dec.

34. Kim SR, Stitik TP, Foye PM, Greenwald BD, **Campagnolo DI**. Critical review of prolotherapy for osteoarthritis, low back pain, and other musculoskeletal conditions: a physiatric perspective. *Am J Phys Med Rehabil*. 83(5):379-89, 2004 May.
35. Millis SR. **Campagnolo DI**. Kirshblum S. Elovic E. Jain SS. DeLisa JA. Improving resident research in physical medicine and rehabilitation: impact of a structured training program. *J. of Spinal Cord Med* 27(5):428-33, 2004.
36. Marrie RA, Cutter G, Tyry T, Hadjimichael O, **Campagnolo DI**, Vollmer T. Validation of the NARCOMS registry: fatigue assessment. *Multiple Sclerosis* 11(5):583-4, 2005 Oct.
37. Marrie RA, Cutter G, Tyry T, Hadjimichael O, **Campagnolo DI**, Vollmer T. Changes in ascertainment of multiple sclerosis. *Neurology* 65(7):1066-1070, 2005 Oct 11.
38. Liu R, La Cava A, Bai X, Jee Y, Price M, **Campagnolo DI**, Christadoss P, Vollmer TL, Van Kaer L, Shi F. Cooperation of iNKT cells and CD4+CD25+ T Regulatory Cells in the Prevention of Autoimmune Myasthenia. *J Immunol*. 175(12):7898-904, 2005 Dec 15.
39. Jee Y, Liu R, Bai XF, **Campagnolo DI**, Shi FD, Vollmer TL. Do Th2 cells mediate the effects of glatiramer acetate in experimental autoimmune encephalomyelitis? *Int Immunol*. 18(4):537-44, April 2006.
40. Marrie RA, Cutter G, Tyry T, Vollmer T, **Campagnolo DI**. Does multiple sclerosis-associated disability differ between races? *Neurology* 66(8):1235-40, 2006 Apr 25.
41. Liu R, Van Kaer L, La Cava A, Price M, **Campagnolo DI**, Collins M, Young DA, Vollmer TL, Shi FD. Autoreactive T cells mediate NK cell degeneration in autoimmune disease. *J Immunol*. 176(9):5247-54, May 1, 2006.
42. **Campagnolo D**. North American Research Committee on Multiple Sclerosis. *International Journal of MS Care*. 2006;8(3)110-111.
43. Marrie RA, Cutter G, Tyry T, Vollmer T, **Campagnolo D**. Disparities in the Management of Multiple Sclerosis-Related Bladder Symptoms. *Neurology* 68(23):1971-8, 2007 Jun 5.
44. Marrie RA, Cutter G, Tyry T, **Campagnolo, DI**, Vollmer, T. Validation of the NARCOMS Registry: Diagnosis. *Multiple Sclerosis* 13(6):770-5, 2007 Jul.
45. Bar-Or A, Vollmer\* T, Antel J, Arnold DL, Bodner CA, **Campagnolo D**, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Robinson WH, Shi FD, Utz PJ, Valone F, Weiner L, Steinman L, Garren H. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase I/II trial. *Arch Neurol* 64(10):1385-6, 2007 Oct.



46. Jee Y, Piao WH, Liu R, Bai XF, Rhodes S, Rodebaugh R, **Campagnolo DI**, Shi FD, Vollmer TL. CD4(+)CD25(+) Regulatory T-cells Contribute to the Therapeutic Effects of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis. *Clinical Immunology*, 125(1):34-42, 2007 Oct.
47. Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, **Campagnolo D**, Arnold D. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. In press *Multiple Sclerosis*
48. Marrie, R.A., Horwitz, R., Cutter, G., Tyry, T., **Campagnolo, D**, & Vollmer, T. Comorbidity, socioeconomic status and multiple sclerosis. *Multiple Sclerosis 2008 (in press)*.
49. Piao WH, Wong R, Bai XF, Huang J, **Campagnolo D**, Dorr RT, Vollmer T, Shi F. Therapeutic effect of anthracene-based anti-cancer agent ethonafide in an animal model of multiple sclerosis. *Journal of Immunology* 179(11):7415-23, 2007 Dec 1.
50. Piao WH, Jee YH, Liu RL, Coons SW, Kala M, Collins M, Young DA, **Campagnolo DI**, Vollmer TL, Bai XF, La Cava A, Shi FD. IL-21 Modulates CD4+ CD25+ Regulatory T-cell Homeostasis in Experimental Autoimmune Encephalomyelitis. *Scandinavian Journal of Immunology* 67(1):37-46, 2008 Jan.
51. Piao WH, Wong R, Bai XF, Huang J, **Campagnolo DI**, Dorr RT, Vollmer TL, Shi FD. Therapeutic Effect of Anthracene-Based Anticancer Agent Ethonafide in an Animal Model of Multiple Sclerosis. *J Immunol* 179:7415-23, 2007 Dec.
52. **Campagnolo DI**, Dixon D, Schwartz J, Bartlett JA, Keller SE. Altered Innate Immunity Following Spinal Cord Injury. *Spinal Cord* Volume 46 (7); 477-481, 2008.
53. Bai Y, Liu R, Huang D, La Cava A, Tang Y, Iwakura Y, **Campagnolo DI**, Vollmer TL, Ransohoff RM, Shi F. CC chemokine ligand 2 (CCL2) is required for recruitment of IL6-producing CD11b<sup>+</sup> monocytes to draining lymph nodes during the initiation of T<sub>H</sub>17-dependent B cell-mediated autoimmunity. In Press *European Journal of Immunology*
54. Marrie RA, Cutter G, Tyry T, **Campagnolo D**, Vollmer T. Patients with Multiple Sclerosis Reliably Report Smoking Status Submitted *American Journal of Epidemiology*

## CHAPTERS

1. Katz RT, **Campagnolo DI**, Goldberg G, Parker JC, Pine ZM, Whyte J. Research in physical medicine and rehabilitation. In: Braddom RL, ed. *Textbook of Physical Medicine and Rehabilitation*. Philadelphia, Pa: W.B. Saunders Publishers; 1996:255-272.
2. **Campagnolo DI**, Horton JA. Rehabilitation prescription for the paraplegic. In: Shankar K, ed. *Exercise Prescription*. Philadelphia, Pa: Hanley and Belfus Inc; 1998:247-264.

3. Shi FD, **Campagnolo DI**, Vollmer TL. Immune therapy for multiple sclerosis: altered peptide ligands and statins. In: Cook S. *Handbook of Multiple Sclerosis, 4th ed.*

## ABSTRACTS

1. **Campagnolo DI**, Bitwinski J, Bach J. Assessment of life satisfaction for ventilator supported polio patients. *Archives of Physical Medicine and Rehabilitation*. 1991;72(10):801-802.
2. DeLisa JA, Jain SS, **Campagnolo DI**. Analysis of factors important in selecting a physical medicine and rehabilitation residency. *American Journal of Physical Medicine and Rehabilitation*. 1992;71(4):251.
3. **Campagnolo DI**, Katz RT. Successful treatment of akinetic mutism with a post-synaptic dopamine agonist. (Abstract) *Archives of Physical Medicine and Rehabilitation*. 1992;73(10):975.
4. Malanga G, **Campagnolo DI**. Clarification of the 'Pronator Reflex.' *Archives of Physical Medicine and Rehabilitation*. 1992;73(10):969.
5. Jain SS, DeLisa JA, **Campagnolo DI**. Chief residents in physiatry: expectations versus training. *American Journal of Physical Medicine and Rehabilitation*. 1993;72(44):234.
6. Campagnolo DI, Linsenmeyer TA, Jacalan C, Pak N, Averill A. Assessment of voiding dysfunction following brain injury. *Archives of Physical Medicine and Rehabilitation*. 1993;74(11):1245.
7. Kirshblum S, **Campagnolo DI**, DeLisa JA. The effect of mandatory clerkship on medical students' perception of physiatry. *Archives of Physical Medicine and Rehabilitation*. 1993;74(11):1236.
8. Kirshblum S, **Campagnolo DI**, DeLisa JA. Opinions of fourth-year medical student applying to PM&R residency programs. *Archives of Physical Medicine and Rehabilitation*. 1993;74(11):1236.
9. Jain SS, DeLisa JA, **Campagnolo DI**. Methods of evaluation of physical medicine and rehabilitation residents' clinical competency. *American Journal of Physical Medicine and Rehabilitation*. 1994;73(2):142.
10. DeLisa JA, Jain SS, **Campagnolo DI**. Factors used by physical medicine and rehabilitation residency training directors to select their residents. *American Journal of Physical Medicine and Rehabilitation*. 1994;73(2):141.
11. **Campagnolo DI**, Keller SE, Sipski ML. Lymphocyte dysfunction following spinal cord injury. *Journal of the American Paraplegia Society*. 1994;17(2):116.
12. **Campagnolo DI**, Keller SE, Sipski ML. Lymphocyte dysfunction in tetraplegics. *Journal of the American Paraplegia Society*. 1994;17(4):197.
13. **Campagnolo DI**, Keller SE, Sipski ML. Immune system dysfunction following spinal cord injury. *American Journal of Physical Medicine and Rehabilitation*. 1994;73(2):141.

14. Ferraro DJ, Sipski ML, **Campagnolo DI**. The rehabilitation of a deaf and mute tetraplegic. *Journal of the American Paraplegia Society*. 1994;17(4):222.
15. **Campagnolo DI**, Keller SE, Grimaldi L. Natural killer cell function in tetraplegic patients. *Archives of PM&R*. 1995;76(11):1032.
16. **Campagnolo DI**, DeLisa JA, Foye PM. Lateral cutaneous nerve of the calf: a nerve conduction technique. American Association of Electrodiagnostic Medicine (AAEM) abstract. *Muscle and Nerve*. October 2000;23(10):1630-1631.
17. Qian T, **Campagnolo DI**, Kirshblum S. High-dose methylprednisolone may do more harm for spinal cord injury. Compendium of Abstracts in *Spinal Cord Medicine*. June 2001;6(1):25.
18. Qian T, **Campagnolo DI**, Kirshblum S, DeLisa J. High-dose methylprednisolone may cause myopathy in patients with acute spinal cord injury. *American Journal of Physical Medicine and Rehabilitation*. 2001;80(4):316.
19. Chen B, Foye PM, **Campagnolo DI**, Stitik TP, Nadler SF, DeLisa JA. Carpal tunnel syndrome after motor vehicle crash. *Archives of PM&R*. September 2001;82(9):1314.
20. Foye PM, Stitik TP, DePrince ML, Nadler SF, **Campagnolo DI**, Chen B, DeLisa JA. Medical students' responses to real versus simulated patients within a musculoskeletal physical exam workshop. *Archives of PM&R*. September 2001;82(9):1333.
21. **Campagnolo DI**, Keller SE, Brandman D, Yeager M. Impaired Cellular Immunity after Spinal Cord Injury. *Am J Phys Med Rehabil*. 2003;82(3):237.
22. **Campagnolo DI**, Bromberg R, Brandman D, DeLisa JA. Enhancing resident physician training with personal digital assistants. *Am J Phys Med Rehabil*. 2003;82(3):238
23. Liu R, Pollard MK, LaCava A, Price M, Rhodes S, **Campagnolo DI**, et al. Treatment of a B cell mediated autoimmune disease, myasthenia gravis in mice by activation of natural killer TT cells. *Neurology*. 2005;64(6) Supplement 1:A78.
24. Marrie RA, Cutter G, Tyry T, Vollmer T, **Campagnolo DI**. NARCOMS validation study. *Neurology*. 66, Supplement 2, P04.109.
25. Marrie RA, Cutter G, Tyry T, Vollmer T, **Campagnolo DI**. Does Multiple Sclerosis-associated disability differ between Races? *Neurology*. 66, Supplement 2. P04.118.
26. Zvonkina VY, **Campagnolo DI**, Frey JL. Effects of sleep deprivation during the 80-hour work week. *Sleep*. 2006;29, Supplement S, A119.

27. Bar-Or A, Antel J, Bodner CA, **Campagnolo DI**, Gianettoni J, Jalili F, Kachuck N, Lapierre Y, Niino M, Oger J, Price M, Rhodes S, Shi F, Steinman L, Valone F, Vollmer T, Weiner L, Garren H. Antigen-specific immunomodulation in multiple sclerosis patients treated with MBP encoding DNA plasmid (BHT-3009) alone or combined with atorvastatin. Submitted AAN 2006.
28. Jee Y, Liu R, Price M, **Campagnolo DI**, Shi FD, Vollmer TL. CD4+CD25+ regulatory T cells contribute to the therapeutic effects of glatiramer acetate in experimental autoimmune encephalomyelitis. 58th American Academy of Neurology Annual Meeting, April 1-8, 2006, San Diego Convention Center in San Diego, CA. (Poster #181. Poster Session P05. April 6, 7:30 a.m.-12:00 p.m.)
29. Campagnolo D, Shi F, Rhodes S, Liu R, Piao W, Kala M, Sood R, Vollmer T. Natural Killer Cell Cytotoxicity in Treatment Naïve Multiple Sclerosis Subjects. Consortium of Multiple Sclerosis Centers 2007 Annual Meeting, Washington D.C.. Poster S14

## REVIEWS

1. Katz RT, **Campagnolo DI**. Pharmacologic management of spasticity. *Physical Medicine and Rehabilitation State of the Art Reviews*. 1994;8(3):473-480.
2. **Campagnolo DI**. Book Review: Handbook of Neurorehabilitation. *American Journal of Rehabilitation*. 1996;75(1):43.
3. **Campagnolo DI**. Book Review: Handbook of Physical Medicine and Rehabilitation Basics. *American Journal of Rehabilitation*. 1996;75(3):231.
4. **Campagnolo DI**, Cheu JW. Central nervous system anatomy. *PM&R State of the Art Review*. 1996;10(3):367-386.
5. **Campagnolo DI**. Guest Editor: *Rehab in Review*. 1999;7(8).
6. **Campagnolo DI**. Invited Commentary on Anderson AJ. Mechanisms and pathways of inflammatory responses in CNS trauma: spinal cord injury. *J Spinal Cord Med*. 2002; 25:178.

## REPORTS

1. Simultaneous Bilateral Patellar Tendon Rupture: A Case Report and Literature Review. Oral presentation at: The First Annual Resident's Research Day. June 20, 1990. Newark, New Jersey.
2. Joint Injection and Aspiration. Grand Rounds; Department of Physical Medicine and Rehabilitation. UMDNJ-New Jersey Medical School. March 1, 1991. Newark, New Jersey.

3. Neck and Back: Biomechanics Didactic Lecture Series. Department of Physical Medicine and Rehabilitation. UMDNJ-New Jersey Medical School. 1990, 1991, & 1992. Newark, New Jersey.
4. Antipsychotic Medications. Traumatic Brain Injury Lecture Series. Kessler Institute for Rehabilitation. June 14, 1991. East Orange, New Jersey.
5. Resident Research Education. AAPM&R Resident Physician Council. Newsletter. June 1992.
6. Complications of Traumatic Brain Injury. Orientation Lecture Series. Department of Physical Medicine and Rehabilitation. UMDNJ-New Jersey Medical School. August 1992 and 1993. Newark, New Jersey.
7. Motor Systems. Resident Didactic Series. Department of Physical Medicine and Rehabilitation. UMDNJ-New Jersey Medical School. September 23, 1992. Newark, New Jersey.
8. Neuropharmacology in Traumatic Brain Injury. Resident Didactic Series. September 1993.
9. Respiratory Dysfunction: Assessment and Management at Acute Care Management of the Spinal Cord Injured Person. Kessler Institute for Rehabilitation. October 15, 1993.
10. Medical Complications of Spinal Cord Injury. Annual Review Course in Physical Medicine and Rehabilitation. UMDNJ-New Jersey Medical School and Kessler Institute for Rehabilitation. 1994-present. Ramada Hotel. East Hanover, New Jersey.
11. Urodynamics Workshop: Voiding Dysfunction Following Brain Injury. Academy of Physical Medicine and Rehabilitation Annual Meeting. 1993.
12. Spinal and Peripheral Control of Immune Function: Basic Mechanisms and Clinical Manifestations. Presented at the Winter Conference on Brain Research. January 1995.
13. Effect of Timing of Stabilization on Length of Stay and Medical Complications Following Spinal Cord Injury. Presented at the 12th Annual North American Spine Society Meeting. October 22-25, 1997.
14. Sanchez W, **Campagnolo DI**. Computer-Based Training of Spinal Cord Injury for Health Care Professionals. Presented at the Eighth Annual Ottawa Conference on Medical Education and Assessment. July 12-15, 1998. Philadelphia, Pennsylvania.
15. **Campagnolo DI**, Bartlett JA, Keller SE. A Review of Level of Injury-Related Immune Alteration Following SCI. American Paraplegia Society. September 7, 1999. Las Vegas, Nevada.

16. Foye PM, Stitik TP, **Campagnolo DI**, Nadler SF, Chen B. Results of Cadaver-Based Anatomy Teaching for PM&R Residents. Poster Presentation. Association of Academic Physiatrists 36th Annual Educational Conference. March 1-4, 2000. San Diego, California.
17. **Campagnolo DI**. Lateral Cutaneous Nerve of the Calf: A Nerve Conduction Technique. American Association of Electrodiagnostic Medicine. 47th Annual Scientific Meeting. September 13-16, 2000. Philadelphia, Pennsylvania.
18. **Campagnolo DI**. Enhancing Resident Physician Training with Personal Digital Assistants (PDAs). Presented at UMDNJ Master Educators' Guild and The Integrated Advanced Information Management Systems (IAIMs) Project. Robert Wood Johnson Medical School. May 3, 2002. Piscataway, New Jersey.
19. Vizcarra G, Dixon D, **Campagnolo DI**, Bartlett JA, Keller SE. Stress, Depression, and TNF in Spinal Cord Injury. Presented at the 10th Annual PsychoNeuroImmunology Research Society. June 4-8, 2003. Amelia Island, Florida.
20. **Campagnolo DI**, Padilla N. Spinal Cord Injury: Computer-Based Distance Learning. Presented at the NJEdge.Net Annual Conference. Technology in Education. October 30, 2003. Plainsboro, New Jersey.